Bevacizumab, a current drug targeting VEGFA, has been approved as part of immunotherapeutic combinations for HCC and has demonstrated remarkable anti-tumor efficacy [53–55]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.